What this trial studies
The purpose of this study is about assessing the utilization of a mobile phone application (app), designed to improve the menopause experience of midlife women experiencing related symptoms and its association with menopause-related health care utilization
Conditions in scope
- Menopausal Symptoms
- Menopause Symptom Management
Interventions
- EMMII (Other) — The tool/app, consists of educational components designed to enable women to more effectively identify menopause symptoms and feel confident in seeking treatment to address their symptoms. The tool/app also produces a tailored menopause discussion guide for patients to bring to…
- Comparison Group (Other) — Receive educational menopause pamphlet describing menopause symptoms and evidence-based treatment options.
Who can join
All sexes · Ages 24 Years to 80 Years
Inclusion criteria
- For Patient Enrollment:
- Women between the ages of 45 and 55
- English speaking (app only available in English)
- Able to provide informed consent
- Experiencing menopause symptoms, which will be assessed by a Menopause Rating Scale (MRS) survey score of ≥ 5
- Has an upcoming Mayo Clinic primary care appointment within 3 weeks of the enrollment and the MRS survey
Exclusion criteria
- Lack of willingness to engage with app
- Inability to provide informed consent
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Rochester | Minnesota | Mayo Clinic | Unknown |
Status & timeline
- Overall status: Enrolling by invitation
- Study type: Interventional
- Phase: N/A
- Start date: 2025-05-07
- Primary completion: 2027-05-15
- Last update posted: 2025-06-04
- First posted: 2025-04-09
Sponsor & contact
Lead sponsor: Mayo Clinic (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Frequency of app logins among intervention group. (Up to 6 weeks)
- Compare differences in rates of menopause treatment among intervention and comparison groups. (Up to 6 weeks)
- Mean score on a validated survey assessing perceived importance and availability of healthcare services for women's health conditions/concerns related to menopause (through study completion, an average of 1 year)
- Percentage of healthcare professionals reporting 'high' & 'low' confidence in diagnosing and managing menopause symptoms (through study completion, an average of 1 year)
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT06919887 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.